Respiratory Syncytial Virus

In vivo efficacy data presented from Alnylam RSV program at AAAAI meeting

Published in Biotech Business Week, April 11th, 2005

Alnylam Pharmaceuticals, Inc., (ALNY) announced the presentation of in vivo efficacy data on its lead candidate RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection at The Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Antonio, Texas.

Experiments performed by researchers at Alnylam and collaborators from the University of Georgia demonstrated that a single low dose of Alnylam's lead RSV candidate, ALN-RSV01, an optimized siRNA, inhibits RSV replication both as a prophylactic and as a treatment when administered by intranasal delivery in a liquid form.

Alnylam collaborator Dr. Ralph...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-04-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry